Embed Size (px)
Citation preview
Wright, 2012 1
Wright, 2012 1
Hypertension and Hyperlipidemia: Latest Diagnostic and Treatment
Options
Wendy L. Wright, MS, RN, ARNP, FNP, FAANPAdult/Family Nurse Practitioner
Owner – Wright & Associates Family Healthcare, PLLCPartner – Partners in Healthcare Education, LLC
Disclosures
• Grants: Novartis, Daiichi-Sankyo
• Speaker Bureau: Ortho-McNeill, Abbott, Novartis, GSK, Sanofi-Pasteur, Daiichi-Sankyo, Merck
Wright, 2012 2
Wright, 2012 3
Objectives
• Upon completion of this lecture, the participant will be able to:
– Identify the various classifications of prehypertension, Stage I and Stage 2 hypertension; and the optimal ranges for various lipid parameters
– Discuss nonpharmacologic treatment options for the patient with hypertension and hyperlipidemia
– Discuss pharmacologic treatment options for the patient with hypertension and hyperlipidemia
Wright, 2012 2
Wright, 2012 4
CVD Is the Most Common Health Problem in the United States
More than 60 million Americans
(>20%) have some form of
cardiovascular disease
Adapted from American Heart Association. Heart Disease and Stroke Statistics – 2003 Update. Dallas, Tex; 2002.
CVD disease mortality trends for males and femalesCVD disease mortality trends for males and females (United United
States: 1979States: 1979--2004). 2004).
SSource: NCHS and NHLBI.ource: NCHS and NHLBI.
400
450
500
550
79 80 85 90 95 00 04
Death
s in
Th
ou
san
ds
Years
Males Females
CVD disease mortality trends for males and females
5Wright, 2012
Wright, 2012 6
Evolution in Understanding Cardiovascular Disease: Total Risk Perspective
Cardiovascular Disease Is an Interplay of Risk Factors
Age Gender
SmokingDyslipidemia Hypertension
Diabetes
Mellitus
Kannel WB. Am J Hypertens. 2000;13:3S-10S; Poulter N. Am J Hypertens. 1999;12:92S-95S.
Wright, 2012 3
Wright, 2012 7
Hypertension and Dyslipidemia Contribute to Atherogenesis
Endothelial
Dysfunction
CVD
Hypertension Dyslipidemia
Atherosclerosis
Smooth Muscle
Cell Contraction
Impaired Bioavailability
of Nitric Oxide
Impaired
Vasodilation
Wright, 2012 8
Impact of Elevated SBP and Total Cholesterol on CHD Mortality in MRFIT
Age-Adjusted CHD
Death Rates
Per 10,000 Person-Years
Cholesterol
Quintile (mg/dL)
SBP Quintile (mm Hg)MRFIT = Multiple Risk Factor Intervention Trial.
Adapted from Neaton JD et al. Arch Intern Med. 1992;152:56-64.
33.7
21
17.1
12.7 12.2
22.6
12.3
8.3 9.6
5.9
17.7
10.98.5
6.35.5
16.7
7.9 7.96
4.3
13.7
5 5.63.4 3.1 <182
182-202
203-220
221-244
≥245
Wright, 2012 9
Hypertension and Dyslipidemia: A Significantly Undertreated Syndrome
Adapted from American Heart Association.Heart Disease and Stroke Statistics—2003 Update; CDC; NHANES III (1988-1994).
27 Million Affected by Both Hypertension and Dyslipidemia
9 milliondiagnosed with both
3 million treated for both
300,000 at bothgoals (~ 1%)
14.7 millionundiagnosed
Wright, 2012 4
10
Impact of Hypertension
• 50 million individuals in the United States have hypertension1
• 277,000 deaths annually in US due to hypertension2
1American Association of Clinical Endocrinologists Medical Guidelines For Clinical Practice for the Diagnosis and Treatment of Hypertension. Endocrine Practice, Vol 12 No. 2 March/April 20062National Center for Health Statistics. Health, United States, 2005, with Chartbook on the Health of Americans. Hyattsville, Maryland: 2004. Available at: http://www.cdc.gov/nchs/hus.htm
Wright, 2012
Hypertension Remains One of the Most Important Multipliers of CV Risk
BP >140/90 mm Hg is associated with:
• 277,000 deaths in 2003
BP, blood pressure; CHF, congestive heart failure; MI, myocardial infarction.
Rosamond W et al. Circulation. 2007;115:1-103.11Wright, 2012
Wright, 2012 12
It is currently estimated that…
• 90% of normotensive 55 year olds will develop hypertension at some point in his/her lifetime
Wright, 2012 5
Statistics
• Nearly 30% of all hypertensive individuals are unaware of their condition
– 42% are not being treated with antihypertensive medication
– 69% do not have their blood pressure (BP) controlled to the level recommended by JNC 7. 1,2
• The prevalence of hypertension will continue to increase as the population ages unless effective preventive actions are implemented.
•Wright, 2012 13
1 Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206.
2 The Seventh Report if the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003;289:2560-2572.
14
Hypertension and Management:Old School
Hypertension = Systemic disease
Hemodynamics altered
Treat the blood pressure
Therapeutic options
BetaBlockers
ACE ARB Diuretics CCB Others
Adapted from Vascular Biology Working Group, University of FloridaCollege of Medicine, Carl Pepine, MD, DirectorWright, 2012
15
Hypertension and Management: New School
Hypertension = Disease of the blood vessels
Vascular biology altered
Treat the vasculature
Therapeutic options
BetaBlockers
ACE ARB Diuretics CCB Others
Adapted from Vascular Biology Working Group, University of FloridaCollege of Medicine, Carl Pepine, MD, DirectorWright, 2012
Wright, 2012 6
Physiology of the Renin Angiotensin System
Ang, angiotensin.
Reid IA. Adv Physiol Edu. 1998;20:S236-S245.
↓↓↓↓ BLOOD PRESSUREBLOOD VOLUME
Activation of Baroreceptor
Reflexes
↑↑↑↑ Renal Sympathetic Nerve Activity
Beta-adrenergicStimulation
↑↑↑↑ RENIN SECRECTION
↓↓↓↓ Renal Artery Pressure
Renal Baroreceptor
↑↑↑↑ BLOOD PRESSUREBLOOD VOLUME
SystemicVasoconstriction
↑↑↑↑ PlasmaAng II
↑↑↑↑ AldosteroneSecretion
↑↑↑↑ PlasmaAng I
16Wright, 2012
17
RAAS and Adipose Tissue
• All components of the RAAS system are expressed in adipose tissue, especially the visceral adipose tissue1,2,3
• Visceral adipose tissue of patients with insulin resistance and Type 2 diabetes is dysfunctional and is a source of chronic low-grade inflammation4
1 Sowers, James R. Insulin Resistance and Hypertension Physiol Heart Circ Physiol. 2004;286:H1597-H1602
2 Ashish, A, El-Atat, R, et al. Hypertension and Obesity Recent Prog Horm Res. 2004;59:169-205.3 Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ Clin Endocrinol Metab. 2004;
98:2548-2556..Wright, 2012
18
RAAS and Endothelial Dysfunction
• Growing body of evidence–Promotion of endothelial dysfunction
–Microalbuminuria1,2
• RAAS Inhibition (ACE, ARB and Direct Renin Inhibitor)–Decreased incidence of new onset Type 2 diabetes
– Improvement in CVD outcomes3
Higashi, Y, Sasaki S, Nakagawa K, et al. Endothelial Function and Oxidative StressIn Renovascular Hypertension N Engl J Med 2002;346:1954-1962.
Wright, 2012
Wright, 2012 7
19
Today –The Hypertensive Patient Exhibits...
• More insulin resistance
• More hyperinsulinemia
• Dyslipidemia
• Microalbuminuria
• Obesity
...as compared to nonhypertensive patients!
Reaven GM. Banting lecture 1988. Role of insulin resistance in human. Disease Diabetes. 1988.37;1595-1607.
Wright, 2012
20
Cardiovascular Disease
Hypertension
Diabetes
Blocking the RAAS has been shown to be beneficial in…
Wright, 2012
Wright, 2012 21
JNC VII: Messages to Clinicians
JAMA. 2003:289:2560-2577.
Wright, 2012 8
Wright, 2012 22
New Messages JNC VII
• The risk of CVD, beginning at 115/75 mm Hg, doubles with each increment of 20/10 mm Hg.
JAMA. 2003:289:2560-2577.
23
CV Disease Risk Doubles with
Each 20/10 mm Hg BP Increment*
*Individuals aged 40-70 years, starting at BP 115/75 mm Hg.CV, cardiovascular; SBP, systolic blood pressure; DBP, diastolic blood pressure
CVdisease
risk
SBP/DBP (mm Hg)
0
1
2
3
4
5
6
7
8
115/75 135/85 155/95 175/105
1. Lewington S, Cardiovascular Issues in Ageing Pilots. et al. Lancet. 2002; 60:1903-1913
2. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, And Treatment of High Blood Pressure. http://jama.ama-assn.org/cgi/content/full/289.19.2560v1. Assessed 5-1-08
Wright, 2012
Wright, 2012 24
Diagnosis
• 2 readings; separated apart
• Patient should not ingest caffeine or smoke for 30 minutes before readings
• Patient should sit for 5 minutes with arm at heart level before blood pressure is checked
Wright, 2012 9
Wright, 2012 25
JNC 7: New Blood Pressure Classification
Blood Pressure ClassificationSBP* DBP*(mm Hg)
Normal<120 and <80
Prehypertension120-139 or 80-89
Stage 1 hypertension140-159 or 90-99
Stage 2 hypertension≥160 or ≥100
*Treatment determined by highest BP category (SBP or DBP).
Adapted from Chobanian AV et al. JAMA. 2003;289:2560-2572; NHBPEPCC. 2003. NIH Publication No. 03-5233.
Wright, 2012 26
Prehypertension
• Individuals with a systolic BP of 120-139 mm HG or a diastolic BP or 80-89 mm HG should be considered as pre-hypertensive and lifestyle modification initiated.
JAMA. 2003:289:2560-2577.
Wright, 2012 27
Most Cases of Hypertension
• Primary hypertension
–Also called essential
–Responsible for 90-95% of all hypertension diagnoses
Wright, 2012 10
Wright, 2012 28
Consider Secondary Causes of HTN
• Sleep apnea
• Drug-induced or drug related– Including OTC medications
• Chronic kidney disease– Polycystic kidneys
• Renal artery stenosis
• Primary aldosteronism
• Renovascular disease
• Chronic steroid therapy and Cushing’s disease
• Pheochromocytoma
• Coarctation of the Aorta
• Thyroid or parathyroid diseaseJAMA. 2003:289:2560-2577.
Wright, 2012 29
What about White-Coat Hypertension?
• Patient involvement in the measurement of his/her blood pressure is recommended, particularly for those individuals whose blood pressure is normal out of the office but consistently elevated in the office
• The office blood pressure of elders is 5 mm Hg higher than their ambulatory blood pressure
• Older the individual, the greater the discrepancy between home and office blood pressures
• No longer considered a benign condition
JAMA. 2003:289:2560-2577.
30
Initial Work-up
• History and review of systems
– Medications and risk factors
• Consider home blood pressure readings with validated blood pressure cuff
• Laboratory workup: CBC, BUN, Creatinine, Glucose, Lipids, GFR, urine - protein
• EKG and/or Echocardiogram, if indicated
• Urine for microalbuminuria Pickering, TG, Hall JE, et al. AHA Scientific Statement: Recommendations for Blood Pressure
Measurement in Humans and Experimental Animals. Part 1: Blood Pressure Measurement in Humans
Hypertension. 2005;45:142-161. Wright, 2012
Wright, 2012 11
Wright, 2012 31
Treatment of Hypertension
Wright, 2012 32
How Helpful is control of BP?
In stage 1 HTN, combined with additional CVD risk factors, achieving a sustained 12 mmHg reduction in SBP over 10 years will prevent 1 death for every 11 patients treated.
JAMA. 2003:289:2560-2577.
33
Benefits of Lowering Blood Pressure
Average Percent Reduction
Stoke: 35% - 40%
MI: 20% - 25%
CHF: 50%
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,And Treatment of High Blood Pressure. http://jama.ama-assn.org/cgi/content/full/289.19.2560v1. Assessed 5-1-08
Wright, 2012
Wright, 2012 12
Wright, 2012 34
Treatment Goals
• < 140/90 mm Hg for those with no complications
• < 130/80 mm Hg for those with diabetes or CRF (per ADA)
• < 130/80 mm Hg – all individuals per NKF
Wright, 2012 35
JNC 7: Algorithm for Treatment of Hypertension
Prehypertension (SBP 120-139 mm Hg or DBP 80-89 mm Hg)
Not at Goal BP (<140/90 mm Hg, or <130/80 mm Hg for patients with
diabetes or chronic kidney disease)
Without Compelling Indications With Compelling Indications
Prehypertension
Stage 1 Hypertension
(SBP 140-159 or DBP 90-99 mm Hg)
Thiazide-type diuretics for most;
may consider ACEI, ARB, BB,
CCB, or combination.
Stage 2 Hypertension
(SBP ≥160 or DBP ≥100 mm Hg)
2-drug combinations for most
(usually thiazide-type diuretics and
ACEI, or ARB, or BB, or CCB).
Drug(s) for compelling indications
Other antihypertensive drugs
(diuretic, ACEI, ARB, BB, CCB)
as needed.
Adapted from NHBPEPCC. 2003. NIH Publication No. 03-5233.
LIFESTYLE MODIFICATIONS
If not at goal BP, optimize dosages or add additional drugs until
goal BP is achieved. Consider consultation with hypertension specialist.
INITIAL DRUG CHOICES
Wright, 2012 36
Wright, 2012 13
Wright, 2012 37
New Messages JNC VII
• The most effective therapy prescribed by the most careful clinician will control hypertension….only if the patient is motivated.
JAMA, May 21, 2003 Vol 289;No 19.
Wright, 2012 38
Lifestyle Modifications to Manage Hypertension
Modification Recommendation Systolic Diastolic ChgsWeight Reduction BMI 18.5-24.9 5-20mm/10 kg wt loss
Adopt DASH eating Diet rich in fruits 8-14 mm Hg
vegetables and low
fat with reduced
saturated and total fat
Dietary Sodium 2.4g Na 2-8 mm Hg
Physical Inactivity Brisk exercise 30” day 4-9 mm Hg
most days of week
Moderation of
Alcohol intake 2 drinks day max 2-4 mm Hg
24 oz beer; 10 oz wine
2 oz 100 proof whiskeyJAMA. 2003:289:2560-2577.
Wright, 2012 39
Lifestyle Modifications
• Dietary sodium reduction
–Most helpful in African Americans and patients with diabetes
–Recommend limiting sodium to < 2000 mg/day for these individuals
• Average individual ingests 4000 mg / day
–ACE inhibitors and diuretics work best with a relatively low sodium diet
Wright, 2012 14
Wright, 2012 40
How Successful Is It?
• Combination of the DASH diet and a dietary sodium reduction to 1600 mg/day is as effective as 1 medication
Wright, 2012 41
Alcohol Intake
• Limit alcohol intake to < 30 mL or 1 ounce of ethanol/day
– Translation: 2 ounces of whiskey
– 10 ounces of wine
– 24 ounces of beer
• Excessive amounts increases treatment resistance
• Also increases risk of a CVA** Women: ½ this amount
Wright, 2012 42
Electrolytes
• Diets high in potassium, calcium and magnesium are associated with a lower blood pressure
• JNC VII recommends an adequate dietary intake of these but does not recommend supplementing from an outside source to lower blood pressure
Wright, 2012 15
Wright, 2012 43
Additional Recommendations
• Omega-3 fatty acids may lower blood pressure
• Caffeine may increase it but tolerance often develops–Most studies do not support a relationship between hypertension and caffeine
• Smoking: discontinuation is important
• Exercise: 30 minutes daily recommended
Wright, 2012 44
Pharmacologic Treatments
Wright, 2012 45
New Messages JNC VII
• Thiazide diuretics should be used in drug treatment for patients with uncomplicated hypertension.
JAMA. 2003:289:2560-2577.
Wright, 2012 16
Wright, 2012 46
Thiazide Diuretics
• Dosing:–Start @ 12.5 mg of HCTZ
– Increase to 25 mg at 6 weeks
• Benefits–55% reduction in CHF
–37% reduction in CVA
–27% reduction in cardiac events
• If not adequately controlled, add additional agents
Chlorthalidone
• Making a come back into thiazide arena
• Dosage: 25 mg once daily
• May increase dosage to 100 mg once daily
Wright, 2012 47
48
Diuretic Precautions
• Electrolyte imbalances
• Syncope/presyncope when combined with ACE/ARB
• Hemoconcentration
• Decrease in urate excretion
• Worsening of insulin resistance at higher doses
• Fatigue
Product inserts accessed 04-20-2008Wright, 2012
Wright, 2012 17
49
Angiotensin Converting Enzyme (ACE) Inhibitors
•Increased nitrous oxide at vessel for vasodilatation•Improved glucose disposal•Reduction in LV geometry changes•Reduction in inflammation•Stabilization of fibrous cap of lipid lesion•Decreased proteinuria •Improves endothelial function•Reduced mortality in patients with CHF•Decreases post-MI mortality
Sato Atsuhisa, Pleiotropic effects of angiotensin-converting enzyme inhibitors; differentiationAmong ace inhibitors may lead to further organ protection. Abstr 21st Sci Meet Int Soc Hypertens2006. 423(2006)
Wright, 2012
50
ACE Inhibitor Trials
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 2000 2001
CONSENSUS I
ValHeFT II
SOLVD treatment
SAVE
AIRE
TRACE
SMILE
CATS
CONSENSUS II
GISSI-3
ISIS-4
PEACE
HOPE
Latini, et al. Curr Perspect. 1995;92:3132-7
CCS-1
CHF
Anterior
AMI
AMI
CAD
LVD
Post-AMI
Wright, 2012
51
ACE Inhibitors PrecautionsACE Inhibitors Precautions
• Hyperkalemia
• Increase in creatinine
• May improve insulin sensitivity
• Decrease in serum Na+ may result in syncope and dizziness when used with diuretics
Product inserts accessed 04-20-2009
• Angioedema
• Cough
Wright, 2012
Wright, 2012 18
52
Effects on Hypoglycemia
• Several studies have shown the ability of ACE inhibition to improve glycemic control – even decrease the risk of hypoglycemia in patients using sulfonylureas.
Thamer M, Ray NF, Taylor T. Association between antihypertensive drug use and
hypoglycemia: A case-control study of diabetic users of insulin or sylfonylureas. Clin Therapeutics 1999; 21:1387
Wright, 2012
53
But…
ACE InhibitorsAre Highly Effective..
Wright, 2012
54
** ** ** **** ** ** **
* = p<0.001 versus placebo* = p<0.001 versus placebo
Plasma ACEPlasma ACE(mmol/ml/min)(mmol/ml/min)
Plasma ANG IIPlasma ANG II(pg/ml)(pg/ml)
**
Placebo 4h 24h 1 2 3 4 5 6Placebo 4h 24h 1 2 3 4 5 6
HospitalHospital MonthsMonthsModified from Modified from JournJourn CardiovascCardiovasc PharmPharm 1982; 9661982; 966--7272
Long Term Effect of Enalapril (20mg)
on Plasma ACE and Angiotensin II
Vascular Biology Working Group, University of Florida
College of Medicine, Carl Pepine, MD, Director
54Wright, 2012
Wright, 2012 19
55
If you block the receptor
site, you don’t have to worry
about the angiotension levels…
AT1
Wright, 2012
56
Angiotensin ReceptorBlockers
Wright, 2012
57
Angiotension Receptor Blockers (ARB’s)
• Utilized since April 1995
• Blocks uptake at receptor site
• Angiotension II produced in locations other than in the lungs
• BP decreased by reducing vascular tone and enhancing NA+ and water clearance
Wright, 2012
Wright, 2012 20
58
Metabolic Effects of ARB’sMetabolic Effects of ARB’s
• Angiotensin II Receptor Blockers
• Metabolically neutral
• No impact on lipids
• No impact on insulin
• No impact on K+
• Lowers uric acid levels
• Minimal side effect profile
Product Inserts accessed 04-20-2009Wright, 2012
59
ARB Trials
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
ValHeFTELITE I
ELITE II
IDNT
RENAAL
IRMA II
OPTIMAAL
LIFE
VALIANT
VALUE
CHARM
MARVAL
ON TARGET
CHF
CV
MI
Renal/CV
Renal
IPreserve
Wright, 2012
ACE vs ARBONTARGET Trial
Goal: 1. Assess the effects of ACE VS ARB in terms of efficacy
2. Assess if the combination ACE & ARB was superior
Results: Telmisartan was found to be “noninferior” to ramipril in patients with vascular disease or high risk diabetes
Combination of these two agents was associated with more adverse events without an increase in benefit.
60
Yusuf, S, Teo KK, Pogue, J et al for the ONTARGET investigators. Telmisartan, ramipril, or both in patients At high risk for vascular events N Engl J Med 2008;358:1547-1559.
Wright, 2012
Wright, 2012 21
61
Beta Blockers
•Reduction in blood pressure•Decreased contractility
•Decreased heart rate•Decreased myocardial oxygen
demand
•Reduction in LVH•Reduced arrhythmias
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,And Treatment of High Blood Pressure. http://jama.ama-assn.org/cgi/content/full/289.19.2560v1. Assessed 5-1-08
Wright, 2012
62
Beta Adrenergic Receptors
• 3 receptors are found in human cardiac myocytes that are coupled to a positive inotropic response and cell growth.–Beta1–Beta2–Alpha1
Hunt, et al. ACC/AHA 2005 Chronic Heart Failure Guideline Update. JACC.2005; 46:1116-43.
Wright, 2012
Beta Blocker Trials
SHEP Systolic Hypertension in the Elderly Program
Step Approach Chlorthalidone/Atenolol
Reduced incidence of major CV events
and CVA; chlorthalidone
decreased CHF
STOP HTN 2
Swedish Trial in Old Persons with
Hypertension
Beta Blocker Vs CCB VS ACE on CV Morbidity
ACE /BB similar efficacy in preventing
CV mortality.
CAPPP Captopril Prevention Project
Beta Blocker + Diuretic vs Captopril
Captopril not better than conventional
HTN Rx in prevention of CV morbidity and mortality; Diabetic
patients on captoprildid better than BB +Diuretics in
decreasing morbidity63
Wright, 2012
Wright, 2012 22
64
Calcium Channel Blockers
Wright, 2012
65
Calcium Channel Blockers
• Effectively treat systolic hypertension
• May be superior to other antihypertensives for stroke prevention
• Effective in patients with:
– Comorbid conditions (Raynauds, migraine)1
• Particularly effective in
– Elderly and African American’s2
1. Materson BJ, Reda DJ, eta l. Single drug therapy for hypertension in men. A comparison of sixAntihypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
2. Tuomilehto J, Rastenyte D, et al. Effects of calcium channel blockade in older patients with Diabetes and hypertension. N Engl J med. 1999;340:677-684.
Wright, 2012
The Calcium Blockers
Dihydropyridines
– Studies of DPH’s effects on
proteinuria have produced conflicting results
– NKF recommends that in
patients who have diabetes
and kidney disease, DPH’s should only be used in
combination with and ACE
or ARB
Nondihydropyridines
– Regression of proteinuria
– Combination of Verapamil +
ACE, reduction in proteinuria can be greater than
achievable with verapamil
alone.
– NKF now recommends adding a NDH to treat hypertension
with an ACE inhibitor or an
ARB to slow the progression of kidney disease.
66
Thornley-Brown D, et al for the African American Study of Kidney Disease and Hypertension Study Group. Differing effects of antihypertensive drugs on the incidence
Of Diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med.2006;166(7):797-805.
National Kidney Foundation. K/DOQI clinical practice guidelines on hypertensionand antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;
43(suppl 1):S1-S290.Wright, 2012
Wright, 2012 23
67
Alpha Blockers
Wright, 2012
68
Alpha BlockersAlpha Blockers• Block postsynaptic Alpha1 Receptors
• Results in vasodilatation
• Relatively inexpensive
• Fair tolerability; May cause postural effects
• Additive agent for older men to decrease BPH symptomatology
• Add-on agent only
• Should never be used as monotherapy due to increased risk of stroke and CHF
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,And Treatment of High Blood Pressure. http://jama.ama-assn.org/cgi/content/full/289.19.2560v1. Assessed 5-1-08
Wright, 2012
69
Centrally Acting Blockers
Wright, 2012
Wright, 2012 24
70
Centrally Acting AgentsCentrally Acting Agents• Stimulates central alpha2 receptors which results in:
– Inhibiting efferent sympathetic activity
• Additive agents
• Should be used 3rd or 4th line
– Examples: Clonidine (catapress, catapress TTS); methyldopa
• Caution: sedation, orthostatic hypotension
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,And Treatment of High Blood Pressure. http://jama.ama-assn.org/cgi/content/full/289.19.2560v1. Assessed 5-1-08
Wright, 2012
71
DirectVasodilators
Wright, 2012
72
Direct VasodilatorsDirect Vasodilators
• Direct smooth muscle vasodilatation, primarily arteriolar
• Two agents
–Apresoline (Hydralazine)
–Minoxidil
**Precautions include: tachycardia, significant peripheral edema and hair growth
**Agents to reduce heart rate may be neededThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,And Treatment of High Blood Pressure. http://jama.ama-assn.org/cgi/content/full/289.19.2560v1. Assessed 5-1-08
Wright, 2012
Wright, 2012 25
73
Aldosterone Antagonists
Wright, 2012
74
• Spironolactone (Aldactone)
• HCTZ / spironolactone (Aldactazide)
• Eplerenone (Inspra)
Aldosterone Antagonists
Wright, 2012
75
Aldosterone as a Therapeutic Target
• Aldosterone promotes:–Retention of sodium
–Loss of magnesium and potassium
–Sympathetic activation
–Parasympathetic inhibition
–Baroreceptor dysfunction
– Impaired arterial compliance
Mac Fadyen RJ, et al Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-34.
Wright, 2012
Wright, 2012 26
76
• May be recommended in the following individuals:–Post MI
–NYHA Class III or IV
–Ejection fraction of < 35%
–Serum creatinine of < 2.5 mg/dl
–K+ < 5.0 mmol/LMardi Gomberg-Maitland, Baran DA, Fuster, V. Treatment of Congestive Heart FailureGuidelines for the Primary Care Physician and Heart Failure Specialist. Arch InternMed 2001;161:324-352et al. ACC/AHA 2005 Chronic Heart Failure Guideline Update. JACC.2005; 46:1116-43.
Aldosterone Antagonists
Wright, 2012
77
Precautions• Must monitor electrolytes
• Must obtain baseline renal function
• Should discontinue the K+ supplement
• Should limit to use in severe heart failure and post MI patients
Clavell, Alfredo L. Common Mistakes made in the Treatment of Congestive Heart Failure. Success with
Failure: New Strategies for Evaluation and Treatment of CHF.
Whistler BC, Canada 8-2000.
Wright, 2012
78
New Classes/Agents
Wright, 2012
Wright, 2012 27
79
Direct Renin Inhibitor
Renin is the enzyme at thebeginning of the RAAS, oneof the key regulating centersfor blood pressure. Blockingthis enzyme can decrease the downstream impact of the RAAS system.
Suppression of the RAAShas been shown to treathypertension and reducetarget organ damage.
Wright, 2012
Direct Renin Inhibition Inhibits the Entire Renin System1-4
Class
ACEI
ARB
Direct Renin Inhibitor (DRI)
PRA Ang I Ang II
Increased peptide levels have not been shown to overcome the blood pressure–lowering effect of these agents.ACEI, angiotensin-converting enzyme inhibitor; Ang, angiotensin; ARB, angiotensin receptor blocker;PRA, plasma renin activity.
1. Johnston CI. Blood Press Suppl. 2000;1:9(suppl 1):9-13.
2.Widdop RE et al. Hypertension. 2002;40:516-520.
3.Fabiani ME et al. Angiotensin II Receptor Antagonists. 2001:263-278.
4. Lin C et al. Am Heart J. 1996;131:1024-1034.80Wright, 2012
Aliskiren
� Dosage:
–150 mg or 300 mg once daily
� Indications:
–Adults with hypertension
Product Insert, 200781Wright, 2012
Wright, 2012 28
New Warning re: Aliskiren
• Do not combine with ACE or ARB
• Avoid use of valturna
–Aliskiren and valdasartan
• Warning followed after early termination of the ALTITUDE trial
–Offered no benefit and was associated with an increased risk of CVA’s
Wright, 2012 82
European Medicines Agency
• The EMA has announced plans to review all aliskiren products and, until the results of this review are available, it has recommended that:
– Aliskiren-containing medicines should not be prescribed to diabetic patients who are also taking an ACE inhibitor or an ARB
– Prescribers should review patients taking aliskiren at a routine (non-urgent) appointment and, if patients are diabetic and are also taking ACE inhibitors or ARBs, aliskiren should be stopped and alternative treatments considered
Wright, 2012 83
http://www.pjonline.com/clinical-pharmacist/2012_jan/avoid_aliskiren_with_ACE_inhibitors_and_ARBs accessed 01-12-2012
Wright, 2012 84
New Messages JNC VII
• Certain high risk conditions are compelling indicationsfor the initial use of other antihypertensive drug classes.
– Angiotensin-converting enzyme inhibitors
– Angiotensin-receptor blockers
– Beta blockers
– Calcium channel blockers
JAMA. 2003:289:2560-2577.
Wright, 2012 29
Wright, 2012 85
JNC 7: Compelling Indications for Individual Antihypertensive Drug Classes
Compelling
Indication*
Recommended Drugs
DIURETIC BB ACEI ARB CCBAldo
ANT
Heart failure • • • • •
Post-MI • • •
High coronary disease
risk• • • •
Diabetes • • • • •
Chronic kidney disease • •
Recurrent stroke
prevention• •
*Compelling indications for antihypertensive drugs are based on benefits from outcome studies or existing clinical guidelines; the compelling indication is managed parallel with the BP.
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; Aldo ANT = aldosterone antagonist; BB = beta-blocker; CCB = calcium channel blocker.
Adapted from NHBPEPCC. 2003. NIH Publication No. 03-5233.
86
Combination Therapy
Wright, 2012
87
When you put your hand in the cabinet…
Wright, 2012
Wright, 2012 30
88
JNC 7 (2003)Combination Therapy
• Most hypertensive patients will require
two or more antihypertensive
medications to achieve goal BP
(<140/90 mm Hg or <130/80 mm Hg in
patients with diabetes/renal disease)
• Initiating therapy with combination
therapy should be considered when BP
is >20/10 mm Hg above goal.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,And Treatment of High Blood Pressure. http://jama.ama-assn.org/cgi/content/full/289.19.2560v1. Assessed 5-1-08 Wright, 2012
89
•“When BP is more than 20/10 mm Hg
above goal, consideration should be given
to initiating therapy with two drugs, either as separate prescriptions or in fixed-dose
combinations.”
•“Failure to titrate or combine medications,
despite knowing the patient is not at goal
BP, represents clinical inertia and must be
overcome.”
JNC 7 (2003)Combination Therapy
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,And Treatment of High Blood Pressure. http://jama.ama-assn.org/cgi/content/full/289.19.2560v1. Assessed 5-1-08 Wright, 2012
90
AASK MAP <92
Target BP (mm Hg)
Multiple Antihypertensive Agents Multiple Antihypertensive Agents
Are Needed to Achieve Target BPAre Needed to Achieve Target BP
No. of antihypertensive agents
1
UKPDS DBP <85
ABCD DBP <75
MDRD MAP <92
HOT DBP <80
Trial 2 3 4
DBP, diastolic blood pressure; MAP, mean arterial pressure; SBP, systolic blood pressure.Bakris GL et al. Am J Kidney Dis. 2000;36:646-661.Lewis EJ et al. N Engl J Med. 2001;345:851-860.
IDNT SBP <135/DBP <85
Wright, 2012
Wright, 2012 31
Wright, 2012 91
Wright, 2012 92
Target Organ Damage
• Heart
– LVH, Angina, CHF, MI
• Brain
– Stroke or TIA
– Dementia
• Chronic Kidney Disease
• Peripheral Vascular Disease
• Retinopathy
JAMA. 2003:289:2560-2577.
Wright, 2012 93
Pick the agent wisely
•Benefits are not the same in antihypertensive therapy at the same commensurate blood pressure control.
American Heart Association Scientific Sessions 2003; November 9-12, 2003,Orlando, Florida, USA.
Wright, 2012 32
Hyperlipidemia
Wright, 2012 94
Many Patients Are Not Reaching Their LDL-C Goal
Adapted from Pearson TA, et al. Arch Intern Med. 2000;160:459-467.
0
10
20
30
40
50
60
70
80
90
100
Low Risk High Risk CHD
Diet/exercise (%)
Drug therapy* (%)
Percent of Patients
Achieving Goal
*Included statins (fluvastatin, lovastatin, pravastatin, simvastatin), gemfibrozil, bile acid sequestrants, niacin, psyllium fiber, or combination drug therapy
282 861 361 1924 108 1352n =
59
70
21
40
8
18
95Wright, 2012
LDL Is the Primary Target
• LDL is the primary target of reduction
– All should be < 100
• Anyone with an LDL > 160 – candidate for pharmacotherapy
• Only exception is the patient with triglycerides > 400 – 500
– Then…target triglycerides first
– Reduce LDL as second goal
96Wright, 2012
Wright, 2012 33
ATP III Recommendations
• Persons with diabetes without CHD raised to level of CHD risk equivalent
• Same for patients with CVD, PVD, aortic aneurysm and chronic renal failure
– This means-LDL must be reduced to under 70
Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497.
97Wright, 2012
Landmark Statin Trials: LDL-C Levels vs Events
Pe
rce
nta
ge
wit
h C
HD
ev
en
t
Primary prevention
Pravastatin
Lovastatin
Modified from Kastelein JJP. Atherosclerosis. 1999;143(suppl 1):S17-S21
Atorvastatin
10
5.4 (210)2.3 (90) 2.8 (110) 3.4 (130) 3.9 (150) 4.4 (170) 4.9 (190)
WOSCOPS-S WOSCOPS-P
0
5AFCAPS-S AFCAPS-P
9
8
7
6
4
3
2
1
ASCOT-P
ASCOT-S
LDL-C, mmol/L (mg/dL)
S = statin treated; P = placebo treated
98Wright, 2012
The Problem with Estimating LDL-C
*Scharnagl H et al. Clin Chem Lab Med 2001 May;39(5):426-31
Estimated or Friedewald LDL-C = TC – HDL-C – TG/5
- Assumes TG to Cholesterol ratio in each VLDL particle is a constant
- Breaks down when TG > 200 or < 100
- Breaks down if you do not fast
- Breaks down when LDL is low
When LDL is 93 mg/dL then Friedewald is 15% falsely low*
When LDL is 61 mg/dL then Friedewald is 19% falsely low*
99Wright, 2012
Wright, 2012 34
• Low HDL-C: <40 mg/dL in men
– < 50 mg/dL in women
• Targets of therapy:
– all persons with low HDL-C: achieve LDL-C goal; then decrease weight, increase physical activity
– those with TG <200 mg/dL: consider drugs for raising HDL-C (fibrates, nicotinic acid)
Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497.
What About HDL?
100Wright, 2012
Important To Talk About Latest AHA Addendum
• HDL elevated to > 50 as optimal for women
– For women whose HDL is < 50; Niacin is recommended or fibrate therapy
– Guidelines also say…dietary supplement niacin “must not be substituted for prescription niacin”
101Wright, 2012
Emerging Risks
• Particle size
– Provides us with the size and total number of the LDL lipoproteins
– Small dense LDL
• Susceptible to oxidation
• Associated with increased vascular permeability
– Associated with insulin resistance syndrome
– What about HDL?
• Size matters also HDL2 (Larger): Most protective
• HDL3 (Small) – Less protective
102Wright, 2012
Wright, 2012 35
Advanced Lipoprotein Panel Highly Abnormal
Basic Lipid Panel –Abnormal
TC= 123LDL = 77
HDL = 24
Trigs= 162
Insulin ResistantAbundance of Lg VLDLAbundance of LDL SmallAbundance of HDL Small
Highly Atherogenic
103Wright, 2012
Insulin Resistance
Syndrome
104Wright, 2012
105Wright, 2012
Wright, 2012 36
106Wright, 2012
Structure of HDL
Rye KA et al. Atherosclerosis 1999;145:227-238.
Hydrophobic CoreHydrophobic Coreof Triglyceride of Triglyceride and Cholesterol and Cholesterol EstersEsters
apoAapoA--IIII
Surface Surface Monolayer of Monolayer of Phospholipids Phospholipids and Free and Free CholesterolCholesterol
apoAapoA--II
107Wright, 2012
Industrial StrengthMost protective
Dust BusterLeast protective
The HDL Molecules(s)
108Wright, 2012
Wright, 2012 37
109Wright, 2012
hsCRP
110Wright, 2012
hsCRP
• CRP is hepatically derived family of proteins that are nonspecific, acute-phase reactant proteins
– CRP normally circulates at very low levels
– Acute inflammatory processes, infections, or tissue injuries induce a marked increase in hepatic synthesis of CRP, which can induce a 100-fold serum increase
Gotto, A.M: Contemporary Diagnosis and Management of Lipid Disorders, 3rd ed. Newtown, Pennsylvania,Handbooks in Health Care Co., Inc. 2004.
111Wright, 2012
Wright, 2012 38
hsCRP
• Atherosclerosis is now linked in part to chronic, low-level inflammation of the vascular endothelium
• Hence, the association with elevated levels of hsCRP
Gotto, A.M: Contemporary Diagnosis and Management of Lipid Disorders, 3rd ed. Newtown, Pennsylvania,Handbooks in Health Care Co., Inc. 2004.
112Wright, 2012
Studies Regarding C-reactive Protein
• 3 year study
• 28,000 postmenopausal healthy women
• High-sensitivity CRP: strongest single predictor of future cardiac events
• Highest levels of ultrasensitive CRP: 5 fold increased risk of developing CHD and a 7 fold increase of having an MI or stroke
Ridker, P.M et. al. C-reactive protein and other markers of inflammation in the
prediction of cardiovascular disease in women. New Engl J Med. 2000;342:836-43.113Wright, 2012
Additional Studies
• Ridker et al. 1998 found an increased risk of cardiovascular events in patients with a baseline hsCRP of 6.6 when compared with a level of 1.2 mg/L–75% greater risk of cardiovascular events
114Wright, 2012
Wright, 2012 39
Study Regarding Obesity and hsCRP
• Human fat cells produce a protein that is linked to both inflammation and an increased risk of heart disease and stroke
• Explains why people who are overweight generally have higher levels of the C-reactive protein (CRP)
Willerson, J.T. et. al. Journal of the American College of Cardiology, September 2005
115Wright, 2012
Who Should Be Tested for hsCRP?
• Individuals who, according to the Framingham Risk Assessment Tool, are at an intermediate risk for the development of cardiovascular disease (10 – 20% risk)
www.aha.org accessed 01/28/07116Wright, 2012
Who Should Be Tested for hsCRP?
• Not for widespread screening of the general adult population; continue to focus on major risk factors, such as high blood pressure, high cholesterol, smoking and diabetes
• Useful as an independent marker of risk and as a “discretionary tool” in the evaluation of those with moderate cardiovascular disease risk to determine treatment course
www.aha.org accessed 01/28/07117Wright, 2012
Wright, 2012 40
Other Expert’s Disagree….
• Many experts believe that this test should be conducted on all patients
–36 studies to date have been conducted on the link between hsCRP and CAD
–All 36 studies have shown a positive relationship
• PHS, WHS, MONICA, ARIC, NHS, HPFS, CHS, EPIC-Norfolk, PIMA are just a few of the studies to show a positive correlation between elevated hsCRP and increased risk for CAD
Ridker, P. Apollo Lecture Series. Brigham and Women’s Hospital; Boston, Mass 2005.
118Wright, 2012
Laboratory Measurements
• hsCRP
– < 1.0 mg/L - low risk of developing cardiovascular disease1
– 1.0 and 3.0 mg/L - average risk1
– > 3.0 mg/L - high risk1
– In the past, it was said that if hsCRP is > 10 mg/L; it was unlikely to be related to cardiovascular inflammation
NO LONGER BELIEVED TO BE TRUE!!1http://www.americanheart.org/presenter.jhtml?identifier=4648 accessed 01/28/07
119Wright, 2012
High vs. Low hsCRP
• This study showed that approximately 10% of the population has an hsCRP level that is undetectable.
–These individuals have an incredibly low event rate and low plaque rupture rate
• Individuals with hsCRP > 10 – 20 had the highest event rate (about 7 fold higher than the individual with a low hsCRP) Ridker, PM. Circulation, 2004; 109:1955-1959
120Wright, 2012
Wright, 2012 41
How Do We Treat hsCRP?
• Lifestyle modification
–Dietary and exercise modifications leading to weight reduction
–Smoking cessation
• Weight loss
–12 weeks of a low-fat diet, hsCRP decreased by 26% in healthy obese women
–Does this reduce events?? Stay tuned…..
Heilbronn LK, Noakes, M, Clifton PM: Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol2001;21:968-970. 121Wright, 2012
How Do We Treat hs-CRP?
• Statins–Can reduce hsCRP by 29% - 50% (fluvastain ER)
– In another study, simvastatin, pravastatin and fluvastatin all reduced CRP by 45%, 66% and 76%
–Best outcomes may be LDL < 70 mg/dL and hsCRP < 2 mg/L
Gotto, A.M: Contemporary Diagnosis and Management of Lipid Disorders, 3rd ed. Newtown, Pennsylvania, Handbooks in Health Care Co., Inc. 2004.
http://www.medscape.com/viewarticle/502691_6 accessed 01/28/07
122Wright, 2012
What is the Target?
• PROVE-IT TIMI 22 Trial
–Patients were randomized to 40 mg/day of pravastatin vs. 80 mg/day of atorvastatin
–Reducing hsCRP to < 2 mg/L improved event-free survival in all patients with ACS regardless of LDL levels
– Lowering hsCRP < 2 was protective even when the LDL was > 70 mg/dL
Internal Medicine World Report, March 2005
123Wright, 2012
Wright, 2012 42
What is the Target?
• REVERSAL Trial–502 patients with documented CHD
–Randomized to 40 mg/day of pravastatin vs. 80 mg/day of atorvastatin• Patients randomized to atorvastatin had less progression of atherosclerosis
–Reducing hsCRP levels provided a benefit in atherosclerosis progression that was independent of the LDL lowering
Nissen, S. NEJM. 2005;352:20 – 28, 29 – 38124Wright, 2012
Treating hsCRP
• Niacin has been shown to reduce hsCRP
• Aspirin has also been shown to reduce hsCRP
• TZD’s and ACE inhibitors can reduce hsCRP
• Omega-3 fatty acids can reduce hsCRP
Hong H, Xu ZM, Pang BS, Cui L, Wei Y, Guo WJ, Mao YL, Yang XC. Effects of simvastain combined with omega-3 fatty acids on high sensitive C-reactive protein,lipidemia, and fibrinolysis in
patients with mixed dyslipidemia. Chin Med Sci J. 2004 Jun;19(2):145-9.
125Wright, 2012
Treatment Options
126Wright, 2012
Wright, 2012 43
HMG CoA Reductase Inhibitors
• Action
– Inhibit the HMG CoA reductase enzyme
– Enzyme is essential for the synthesis of cholesterol
– Also increases the uptake of LDL by the liver
– Additional properties:
• Smooth muscle cell proliferation, platelet aggregation and deposition, fibrinogen, endothelial vasodilation and blood viscosity are also affected by the statins
• May indicate that these medications should be used with diabetes, hypertriglyceridemia, and for stroke prevention
127Wright, 2012
* Nonfatal MI/CHD death
‡ Primary Prevention† Secondary Prevention
** Normal cholesterol levels
The Lancet 1994;344:1383-1389 JAMA 1998:279:1615-1622.
N Engl J Med 1995;333:1301-1307. N Engl J Med 1998;339:1329-1357
N Engl J Med 1996;335:1001-1009
Recent Landmark Coronary Prevention Recent Landmark Coronary Prevention Recent Landmark Coronary Prevention Recent Landmark Coronary Prevention Recent Landmark Coronary Prevention Recent Landmark Coronary Prevention Recent Landmark Coronary Prevention Recent Landmark Coronary Prevention StudiesStudiesStudiesStudiesStudiesStudiesStudiesStudiesStudy Drug N Duration
(Years)Main Findings
4S† simvastatin 4,444 5 ↓↓↓↓30% total mortality
↓↓↓↓34% coronary events*
WOS‡ pravastatin 6,595 5 ↓↓↓↓31% coronary events
↓↓↓↓22% total mortality
CARE† **
pravastatin 4,159 5 ↓↓↓↓24% coronary events
↓↓↓↓31% stroke
AFCAPS/TexCAPS‡ **
lovastatin 6,605 5 ↓↓↓↓37% coronary events/unstable angina
Low HDL population
LIPID† pravastatin 9,014 6 ↓↓↓↓22% total mortality
↓↓↓↓24% death from CHD
128Wright, 2012
Events* in the Major Prevention TrialsEvents* in the Major Prevention TrialsEvents* in the Major Prevention TrialsEvents* in the Major Prevention TrialsEvents* in the Major Prevention TrialsEvents* in the Major Prevention TrialsEvents* in the Major Prevention TrialsEvents* in the Major Prevention Trials*Nonfatal MI/CHD death
Trial N # of # of RR % Events
Events Events Reduction Not Avoided
Placebo Statin %
4S 4444 622 431 34 69
WOS 6595 248 174 31 70
CARE 4159 274 212 24 77
AFCAPS/ 6605 215 163 25 76
TexCAPS
LIPID 9014 715 557 24 78
129Wright, 2012
Wright, 2012 44
Important Information
• Statins may increase risk of diabetes
– Studies now confirm this in both men and women
• Statins may be administered to children age 10 and up with markedly elevated LDL’s unresponsive to traditional therapy
• Rule of 6’s
• Newest statin: pitavastatin (Livalo)
• No longer need to monitor liver enzymes on scheduled basis; clinician judgement
Wright, 2012 130
Why Are We Reducing Events By Only 24%
• 80% of individuals are on monotherapy with statins
– Majority of individuals are in need of combination therapy
• Must consider each component of the lipid panel independently
– A great LDL does not negate the risks associated with a low HDL
– A great HDL does not negate the risks associated with a high LDL
• Target LDL 1st – unless trigs > 400 – 500
• Then target - HDL
131Wright, 2012
-----
*Risk of coronary heart disease over 4 years of follow-up for men ages 50 to 70.
CORONARY HEART DISEASE RISK
HDL vs. LDL as a PredictorHDL vs. LDL as a PredictorHDL vs. LDL as a PredictorHDL vs. LDL as a Predictor
0.0
1.0
2.0
3.0
100 160 220 8565
4525
LDL (mg/dl)LDL (mg/dl)
HDL (mg/dl)HDL (mg/dl)
Risk of CHD Data from Framingham Study
After 4 Yrs*
3.0
2.0
1.0
132Wright, 2012
Wright, 2012 45
Framingham Data…
• This landmark study very clearly demonstrated that for every 4 mg/dL HDL is decreased, there is a 10% increase in CAD
• This is independent of any other risk factors
133Wright, 2012
Framingham Offspring Study: Multiplier for HDL-Cholesterol Level*
HDL HDL
cholesterolcholesterol
3030
3535
4040
4545
5050
5555
6060
6565
7070
MenMen
1.821.82
1.491.49
1.221.22
1.001.00
0.820.82
0.670.67
0.550.55
0.450.45
——
WomenWomen
——
——
1.941.94
1.551.55
1.251.25
1.001.00
0.800.80
0.640.64
0.520.52
Castelli WP. Castelli WP. Am Heart J.Am Heart J. 1983;106:11911983;106:1191--1200.1200.
**Relative increase or decrease of CHD risk according to HDL cholesterol value. Relative increase or decrease of CHD risk according to HDL cholesterol value. Multiply the patient’s general risk by the number opposite the HDL cholesterol value.Multiply the patient’s general risk by the number opposite the HDL cholesterol value.
134Wright, 2012
Nicotinic Acid
• Examples
–Niacin (Immediate release)
–Niaspan (Extended release)
135Wright, 2012
Wright, 2012 46
Niacin – OTC Preparations
• Recent study of “NO flush Niacin” products revealed:
–None of the 8 products marketed as no flush niacin had any niacin in them
Prescriber’s Letter, 2004136Wright, 2012
Mechanism of Action of Niacin
Niacin
↓Adipose tissue ↓FA synthesis/
FA mobilization esterification
↓TG Synthesis
↓Large TG-rich
VLDL
↓ Small dense LDL
↓ Assembly of Apo B containing
Lipoproteins / ↑ Apo B
degradation
↓VLDL, LDL
Niacin
↓ HDL-catabolism
receptor
↓ HDL Apo A-1
Uptake/removal
↑ Apo A-1/reverse
Cholesterol
Transport137Wright, 2012
VA-HIT Results: Major Study Showing HDL Improvement Does Matter!
-35
-30
-25
-20
-15
-10
-5
0
5
10
LDL HDL TG Non fatal
MI
CHD-
Death
Stroke
% C
han
ge
% C
han
ge
N Engl J Med. 1999:341:410-418† Investigator designated
0%0%
6%6%**
-31%31%**
--23%23%** --22%22%****
--29%29%**
*p≤0.05
**p=0.07
†
138Wright, 2012
Wright, 2012 47
Not Everyone Deserves Niacin
• Recent information:
– Individuals with heart disease and LDL < 70 mg/dL show no benefit from increasing HDL with niacin (AIM HIGH TRIAL)
–High dose Niacin was added to simvastatin
–Studied was concluded at 18 months when no benefit was seen; followed for 36 months
–Despite raising HDL, no improved outcomes
Wright, 2012 139
What About Combination Therapy?
• Increasingly becoming the norm
• Particularly in individuals with insulin resistance syndrome
• HATS Trial addressed this issue
140Wright, 2012
HATS Trial:HDL–Atherosclerosis Treatment Study
• 160 CAD patients– HDL < 40 mg/dL in women
– HDL < 35 mg/dL in men
• Randomized– Simvastatin (13 mg/d) and niacin (mean 2.4 g/d)
– Antioxidants (Vitamin E, vitamin C, Beta-carotene, selenium
• Outcomes– CV events (death, MI, stroke, revascularization)
– Arteriographic change in coronary stenosis
• Follow-up, 3 years141Wright, 2012
Wright, 2012 48
*P<0.05 vs baseline.
HATS: Primary Lipid Level Changes
HATS: Primary Lipid Level Changes
Brown BG et al. N Engl J Med. 2001;345:1583-1591.
-9*
-42*
6*
26*
-3
-38*
-50
-40
-30
-20
-10
0
10
20
30
LDL-C HDL-C TG
Placebo
Simva + Niacin
% Change % Change fromfrom
BaselineBaseline
142Wright, 2012
HATS: Conclusions
• In patients with CHD and low HDL-C, combination simvastatin and niacin:
– Decreased LDL-C by 42% and raised HDL-C by 26%
– Resulted in a significant regression in mean coronary stenosis (0.4%) and a reduction of coronary events by 89% over 3 years of treatment
– The combination of simvastatin plus niacin may be beneficial in patients with diabetes
143Wright, 2012
HATS: Clinical Endpoints
0
5
10
15
20
25
1st Qtr
Placebo
Simva+Nia
Antioxid
S+N+A
Coronary Death, MI, Stroke, or Revascularization
89% reduction
23.7
2.6
21.4
14.3
Composite
Event
Rate
%
144Wright, 2012
Wright, 2012 49
Bile Acid Sequestrants
• “Resins”
• Indications: Hyperlipidemia; Particularly LDL
• Examples:
–Cholestyramine (Questran)
–Colestipol (Colestid)
–Colesevelam HCL (Welchol)145Wright, 2012
Welchol
• Welchol (Colesevelam HCL)
• Dosage: 625 mg
– 3 tablets bid or 6 tablets qd; Maximum 7 tablets/day
• With a statin: 4 – 6 tablets daily
– Take with food
• Indications
– Adjunct to diet and exercise to reduce LDL cholesterol
– May be used alone or in combination with a statin
146Wright, 2012
Welchol
• Results
–LDL reduction: 2% - 20% (lowest –highest doses)
–Total cholesterol reduction (8%)
–HDL improvement (8 – 11%)
–May increase triglycerides
147Wright, 2012
Wright, 2012 50
Bile Acid Sequestrants
• Side effects
–GI side effects are the most common
–Elders: may be at risk for a fecal impaction
–Decreased vitamin/medication absorption
–May also increase bleeding tendencies
148Wright, 2012
Bile Acid Sequestrants
• Precautions
–Decreased absorption of thyroxine, digoxin, anticoagulants, thiazide diuretics, propranolol, furosemide, statin drugs
–Dose these medications 1 hour before or 4 hours after the bile acid binding resins
149Wright, 2012
Fibric Acid Derivatives
• “Fibrates”
• Indications
–Hypertriglyceridemia with a family history of atherosclerosis
• Examples
–Lopid (gemfibrozil)
–Tricor (fenofibrate)
150Wright, 2012
Wright, 2012 51
Fibric Acid Derivatives
• Mechanism of Action
–Increase the clearance of VLDL from the plasma and therefore increase the secretion of cholesterol into bile
• Dosing
–Lopid (gemfibrozil): 600mg bid
–Tricor (fenofibrate): •48 mg and 145 mg once daily
151Wright, 2012
Fibric Acid Derivatives
• Results
–Triglyceride reduction: 20-50%
–HDL increase: 10-15%
–LDL +/-
– Limited data regarding long-term benefits of fibrate therapy
• Side effects
–Generally well tolerated
152Wright, 2012
Fibric Acid Derivatives
• Side effects
–Gastrointestinal complaints including nausea, dyspepsia, abdominal and epigastric pain, vomiting
–Rash
–Accentuates anticoagulants
–Elevated LFTs
153Wright, 2012
Wright, 2012 52
Significant FDA Warnings
• Combination of fibrate including fenofibric acid (Trilipix) in combination with statin
• Increased risks of rhabdomyolysis
Wright, 2012 154
Ezetamibe (Zetia): A Cholesterol Absorption Inhibitor
• Dosage: 10 mg once daily
• Efficacy: 18% reduction in LDL when used as monotherapy
–When added to a statin – 25% reduction in LDL
155Wright, 2012
Other Therapies
156Wright, 2012
Wright, 2012 53
Formerly - Omacor Now - Lovaza
• Omega-3 Fatty Acids
• 1 gram capsules
• Dosages: 4 capsules daily
• Indications: reduce triglyceride levels in excess of 500 mg/dL
• Precautions: bleeding, anticoagulants
• Side effects: Burping
157Wright, 2012
Fish Oils
• AHA recommending 1 gram per day of fish oils for those with heart disease
• First prescription drug containing omega – 3 fatty acids (EPA and DHA)
• Lowers triglycerides as much as 45%
–More concentrated (meaning they contain 3x more EPA and DHA than OTC products)
158Wright, 2012
One Regimen
• Flax Seed daily– Shown to reduce total cholesterol and LDL
– No research to support lower morbidity and mortality
• Red Yeast Rice daily– Previously equivalent to approximately 10 mg of lovastatin (Mevacor)
– No longer the case
– No statin-like active ingredient
159Wright, 2012
Wright, 2012 54
Benecol
• Benecol, Right Start, Take Control
–All spreadable “margarine” like products that have been shown to reduce LDL by approximately 15%
–Can certainly be added to statin, niacin, fibrate or bile acid sequestrant
•Dosage: 2 – 3 tbsp per day
160Wright, 2012
Advances in the Prevention of CHD
• LDL-C
• HDL-C
• Lipid subclasses
• C-reactive protein
• Combination
therapy
161Wright, 2012
Thank You For Your Time and Attention!
162Wright, 2012
